662 related articles for article (PubMed ID: 29678638)
1. Comprehensive Analysis of the Activation and Proliferation Kinetics and Effector Functions of Human Lymphocytes, and Antigen Presentation Capacity of Antigen-Presenting Cells in Xenogeneic Graft-Versus-Host Disease.
Kawasaki Y; Sato K; Hayakawa H; Takayama N; Nakano H; Ito R; Mashima K; Oh I; Minakata D; Yamasaki R; Morita K; Ashizawa M; Yamamoto C; Hatano K; Fujiwara SI; Ohmine K; Muroi K; Kanda Y
Biol Blood Marrow Transplant; 2018 Aug; 24(8):1563-1574. PubMed ID: 29678638
[TBL] [Abstract][Full Text] [Related]
2. Graft-versus-leukemia and graft-versus-host reactions after donor lymphocyte infusion are initiated by host-type antigen-presenting cells and regulated by regulatory T cells in early and long-term chimeras.
Xia G; Truitt RL; Johnson BD
Biol Blood Marrow Transplant; 2006 Apr; 12(4):397-407. PubMed ID: 16545723
[TBL] [Abstract][Full Text] [Related]
3. STING negatively regulates allogeneic T-cell responses by constraining antigen-presenting cell function.
Wu Y; Tang CA; Mealer C; Bastian D; Hanief Sofi M; Tian L; Schutt S; Choi HJ; Ticer T; Zhang M; Sui X; Huang L; Mellor AL; Hu CA; Yu XZ
Cell Mol Immunol; 2021 Mar; 18(3):632-643. PubMed ID: 33500563
[TBL] [Abstract][Full Text] [Related]
4. Post-hematopoietic cell transplantation control of graft-versus-host disease by donor CD425 T cells to allow an effective graft-versus-leukemia response.
Jones SC; Murphy GF; Korngold R
Biol Blood Marrow Transplant; 2003 Apr; 9(4):243-56. PubMed ID: 12720217
[TBL] [Abstract][Full Text] [Related]
5. Recipient nonhematopoietic antigen-presenting cells are sufficient to induce lethal acute graft-versus-host disease.
Koyama M; Kuns RD; Olver SD; Raffelt NC; Wilson YA; Don AL; Lineburg KE; Cheong M; Robb RJ; Markey KA; Varelias A; Malissen B; Hämmerling GJ; Clouston AD; Engwerda CR; Bhat P; MacDonald KP; Hill GR
Nat Med; 2011 Nov; 18(1):135-42. PubMed ID: 22127134
[TBL] [Abstract][Full Text] [Related]
6. Mechanisms of antigen presentation to T cells in murine graft-versus-host disease: cross-presentation and the appearance of cross-presentation.
Wang X; Li H; Matte-Martone C; Cui W; Li N; Tan HS; Roopenian D; Shlomchik WD
Blood; 2011 Dec; 118(24):6426-37. PubMed ID: 21963602
[TBL] [Abstract][Full Text] [Related]
7. Chloroquine treatment affects T-cell priming to minor histocompatibility antigens and graft-versus-host disease.
Schultz KR; Bader S; Paquet J; Li W
Blood; 1995 Dec; 86(11):4344-52. PubMed ID: 7492796
[TBL] [Abstract][Full Text] [Related]
8. A crucial role for host APCs in the induction of donor CD4+CD25+ regulatory T cell-mediated suppression of experimental graft-versus-host disease.
Tawara I; Shlomchik WD; Jones A; Zou W; Nieves E; Liu C; Toubai T; Duran-Struuck R; Sun Y; Clouthier SG; Evers R; Lowler KP; Levy RB; Reddy P
J Immunol; 2010 Oct; 185(7):3866-72. PubMed ID: 20810991
[TBL] [Abstract][Full Text] [Related]
9. A Novel Xenogeneic Graft-Versus-Host Disease Model for Investigating the Pathological Role of Human CD4
Ito R; Katano I; Kawai K; Yagoto M; Takahashi T; Ka Y; Ogura T; Takahashi R; Ito M
Am J Transplant; 2017 May; 17(5):1216-1228. PubMed ID: 27862942
[TBL] [Abstract][Full Text] [Related]
10. Alloreactive memory T cells are responsible for the persistence of graft-versus-host disease.
Zhang Y; Joe G; Hexner E; Zhu J; Emerson SG
J Immunol; 2005 Mar; 174(5):3051-8. PubMed ID: 15728519
[TBL] [Abstract][Full Text] [Related]
11. PRO 140 Monoclonal Antibody to CCR5 Prevents Acute Xenogeneic Graft-versus-Host Disease in NOD-scid IL-2Ry
Burger DR; Parker Y; Guinta K; Lindner D
Biol Blood Marrow Transplant; 2018 Feb; 24(2):260-266. PubMed ID: 29128556
[TBL] [Abstract][Full Text] [Related]
12. Daratumumab Prevents Experimental Xenogeneic Graft-Versus-Host Disease by Skewing Proportions of T Cell Functional Subsets and Inhibiting T Cell Activation and Migration.
Gao Y; Shan W; Gu T; Zhang J; Wu Y; Li X; Zeng X; Zhou H; Chen Z; Xiao H
Front Immunol; 2021; 12():785774. PubMed ID: 34987512
[TBL] [Abstract][Full Text] [Related]
13. The effect on the proliferation and apoptosis of alloreactive T cells of cell dose in a murine MHC-mismatched hematopoietic cell transplantation model.
Fujioka T; Taniguchi Y; Masuda T; Nishida S; Ikegame K; Kawakami M; Tsuboi A; Hosen N; Murakami M; Oji Y; Oka Y; Sugiyama H; Kawase I; Ogawa H
Transpl Immunol; 2003; 11(2):187-95. PubMed ID: 12799203
[TBL] [Abstract][Full Text] [Related]
14. Characterization of graft-versus-host disease in SCID mice and prevention by physicochemical stressors.
Sheng-Tanner X; McKerlie C; Spaner D
Transplantation; 2000 Dec; 70(12):1683-93. PubMed ID: 11152097
[TBL] [Abstract][Full Text] [Related]
15. Acute graft-vs-host disease: pathobiology and management.
Goker H; Haznedaroglu IC; Chao NJ
Exp Hematol; 2001 Mar; 29(3):259-77. PubMed ID: 11274753
[TBL] [Abstract][Full Text] [Related]
16. Understanding the alloresponse: new approaches to graft-versus-host disease prevention.
Teshima T; Ferrara JL
Semin Hematol; 2002 Jan; 39(1):15-22. PubMed ID: 11799525
[TBL] [Abstract][Full Text] [Related]
17. Lack of acute xenogeneic graft- versus-host disease, but retention of T-cell function following engraftment of human peripheral blood mononuclear cells in NSG mice deficient in MHC class I and II expression.
Brehm MA; Kenney LL; Wiles MV; Low BE; Tisch RM; Burzenski L; Mueller C; Greiner DL; Shultz LD
FASEB J; 2019 Mar; 33(3):3137-3151. PubMed ID: 30383447
[TBL] [Abstract][Full Text] [Related]
18. A CD8 DE loop peptide analog prevents graft-versus-host disease in a multiple minor histocompatibility antigen-mismatched bone marrow transplantation model.
Choksi S; Kim JC; Whitaker-Menezes D; Murphy GF; Friedman TM; Korngold R
Biol Blood Marrow Transplant; 2004 Oct; 10(10):669-80. PubMed ID: 15389433
[TBL] [Abstract][Full Text] [Related]
19. Collateral damage of nonhematopoietic tissue by hematopoiesis-specific T cells results in graft-versus-host disease during an ongoing profound graft-versus-leukemia reaction.
van der Zouwen B; Kruisselbrink AB; Frederik Falkenburg JH; Jedema I
Biol Blood Marrow Transplant; 2014 Jun; 20(6):760-9. PubMed ID: 24607556
[TBL] [Abstract][Full Text] [Related]
20. Host dendritic cells alone are sufficient to initiate acute graft-versus-host disease.
Duffner UA; Maeda Y; Cooke KR; Reddy P; Ordemann R; Liu C; Ferrara JL; Teshima T
J Immunol; 2004 Jun; 172(12):7393-8. PubMed ID: 15187116
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
